Abstract
Arsenic trioxide (As₂O₃) has recently been identified as an effective drug in different types of cancer therapy. It is a useful pharmacological agent in acute promyelocytic leukemia (APL) treatment, especially the form that is resistant to conventional chemotherapy with all-trans retinoic acid (ATRA). What is more, laboratory data suggest that As₂O₃ is also active when it comes to several solid tumor cell lines. However, the mechanism of action is not fully understood. As₂O₃ in high doses triggers apoptosis, while in lower concentrations it induces partial differentiation. The As₂O₃ mechanism of action involves effects on mitochondrial transmembrane potential which lead to apoptosis. It also acts on the activity of JNK kinase, glutathione, caspases, NF-ĸB nuclear factor or pro- and antiapoptotic proteins. This publication presents the current knowledge about the influence of arsenic trioxide in cancer cells.
| Translated title of the contribution | Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy |
|---|---|
| Original language | Other |
| Pages (from-to) | 817-27 |
| Number of pages | 11 |
| Journal | Postepy higieny i medycyny doswiadczalnej (Online) |
| Volume | 67 |
| Publication status | Published - 6 Aug 2013 |
Keywords
- Antineoplastic Agents
- Apoptosis
- Apoptosis Regulatory Proteins
- Arsenicals
- Caspases
- Cell Differentiation
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Promyelocytic, Acute
- MAP Kinase Kinase 4
- Mitochondria
- NF-kappa B
- Neoplasms
- Oxides
- English Abstract
- Journal Article
- Review